Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022

SELL
$7.67 - $25.8 $481,330 - $1.62 Million
-62,755 Reduced 13.56%
399,875 $3.21 Million
Q2 2022

Aug 09, 2022

SELL
$16.35 - $27.5 $1.23 Million - $2.06 Million
-75,000 Reduced 13.95%
462,630 $10.2 Million
Q1 2022

May 13, 2022

SELL
$15.98 - $19.65 $50,832 - $62,506
-3,181 Reduced 0.59%
537,630 $10.1 Million
Q4 2021

Feb 10, 2022

SELL
$13.28 - $18.0 $215,773 - $292,464
-16,248 Reduced 2.92%
540,811 $8.56 Million
Q3 2021

Nov 12, 2021

BUY
$13.14 - $20.97 $7.32 Million - $11.7 Million
557,059 New
557,059 $9.61 Million

Others Institutions Holding PHVS

About Pharvaris N.V.


  • Ticker PHVS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 33,766,000
  • Market Cap $625M
  • Description
  • Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, r...
More about PHVS
Track This Portfolio

Track Pictet Asset Management Sa Portfolio

Follow Pictet Asset Management Sa and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pictet Asset Management Sa, based on Form 13F filings with the SEC.

News

Stay updated on Pictet Asset Management Sa with notifications on news.